CSF2 and cancer: T-VEC was the first FDA-approved OV for cancer therapy because it was created to selectively proliferate in cancerous cell and increases the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) to boost systemic anticancer immune responses (133).